Autophagy in major human diseases

DJ Klionsky, G Petroni, RK Amaravadi… - The EMBO …, 2021 - embopress.org
Autophagy is a core molecular pathway for the preservation of cellular and organismal
homeostasis. Pharmacological and genetic interventions impairing autophagy responses …

Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration

M Verma, BN Lizama, CT Chu - Translational neurodegeneration, 2022 - Springer
Glutamate is the most commonly engaged neurotransmitter in the mammalian central
nervous system, acting to mediate excitatory neurotransmission. However, high levels of …

Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis

MX Henderson, EJ Cornblath, A Darwich, B Zhang… - Nature …, 2019 - nature.com
Studies of patients afflicted by neurodegenerative diseases suggest that misfolded proteins
spread through the brain along anatomically connected networks, prompting progressive …

[HTML][HTML] Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes

CA Boecker, J Goldsmith, D Dou, GG Cajka… - Current Biology, 2021 - cell.com
Parkinson's disease-causing mutations in the leucine-rich repeat kinase 2 (LRRK2) gene
hyperactivate LRRK2 kinase activity and cause increased phosphorylation of Rab GTPases …

[HTML][HTML] Parkinson's disease: animal models and dopaminergic cell vulnerability

J Blesa, S Przedborski - Frontiers in neuroanatomy, 2014 - frontiersin.org
Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the
global population over 65 years of age. A hallmark feature of PD is the degeneration of the …

Autophagy in neurodegenerative diseases: a hunter for aggregates

H Park, JH Kang, S Lee - International Journal of Molecular Sciences, 2020 - mdpi.com
Cells have developed elaborate quality-control mechanisms for proteins and organelles to
maintain cellular homeostasis. Such quality-control mechanisms are maintained by …

Therapeutics in the pipeline targeting α-synuclein for Parkinson's disease

HG Jasutkar, SE Oh, MM Mouradian, E Barker - Pharmacological reviews, 2022 - Elsevier
Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …

Interplay of LRRK2 with chaperone-mediated autophagy

SJ Orenstein, SH Kuo, I Tasset, E Arias, H Koga… - Nature …, 2013 - nature.com
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial
Parkinson's disease. We found LRRK2 to be degraded in lysosomes by chaperone …

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences

N Exner, AK Lutz, C Haass, KF Winklhofer - The EMBO journal, 2012 - embopress.org
Neurons are critically dependent on mitochondrial integrity based on specific morphological,
biochemical, and physiological features. They are characterized by high rates of metabolic …

Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells

J Tran, H Anastacio, C Bardy - NPJ Parkinson's disease, 2020 - nature.com
Parkinson's disease (PD) is the second most prevalent neurological disorder and has been
the focus of intense investigations to understand its etiology and progression, but it still lacks …